Upcoming Webinar: Empowering Breast Health: Personalized Approaches to Canadian Breast Cancer Screening

Join CanPath for an upcoming webinar from CanPath’s incoming Executive Director, Dr. Jennifer Brooks entitled, “Empowering Breast Health: Personalized Approaches to Canadian Breast Cancer Screening” on  Thursday, October 19th from 12-1pmEST/1-2pmAST. Details and registration info: https://canpath.ca/2023/09/webinar-breast-cancer-screening-brooks/

CanPath is Hiring: Research Operations Manager

Join the CanPath team as the new Research Operations Manager at the University of Toronto. Deadline: September 22, 2023. “CanPath is Canada’s largest population health cohort and a national platform for population-level health research. CanPath is studying the biology, behaviours and environments of Canadians to learn more about the causes of chronic disease and cancer for the good of our country and people around the world. As the CanPath Research Operations Manager, you will be integral to maximizing research funding, which includes conducting detailed analysis and applying and interpreting relevant policies. You will be responsible for directing the activities of a group of staff and therefore will be working together to drive CanPath’s objectives. Using your analytical, communication and problem-solving skills, you will support and collaborate with a diverse set of stakeholders and partners in applying and interpreting policies and procedures, policy issues, and drafting contracts and agreements.” Details: https://jobs.utoronto.ca/job/Toronto-CanPath-Research-Operations-Manager-ON/573838317/  

CanPath Scientific Director presents at AGBT Meeting

Advances in Genome Biology and Technology (AGBT) is “considered the preeminent genome science and technology conference where top global researchers, leaders and innovators meet to announce new discoveries, cutting edge breakthroughs and to collaborate.” CanPath Scientific Director, Dr. Philip Awadalla attended the AGBT Precision Health meeting in San Diego, California from September 7-9, 2023. Dr. Awadalla was a panelist speaking about The Great Debate, Genetics, Environment, and Health, alongside Dr. Gary Miller (Columbia University) and Dr. Alison Motsinger-Reif (National Institute of Environmental Health Sciences).

New Publication – Depression, Anxiety and Risk of Cancer

We are pleased to share that the first results from the Psychosocial Factors and Cancer Incidence (PSY-CA) consortium have been published in Cancer. Led from the Netherlands by Dr. Lonneke van Tuijl and Dr. Joost Dekker, this study includes 18 cohorts with more than 300,000 participants including Atlantic PATH, the Ontario Health Study and CARTaGENE from CanPath. Our local team members include Mr. Yunsong Cui (Atlantic PATH) who completed all local analyses, Dr. Ellen Sweeney (Atlantic PATH) and Dr. Melanie Keats (Dalhousie University). Depression and anxiety have long been hypothesized to be related to an increased cancer risk, but, to date, findings are inconclusive. Individual participant data meta-analyses were performed within the PSY-CA consortium to assess the associations between depression, anxiety, and the incidence of various cancer types (overall, breast, lung, prostate, colorectal, alcohol-related, and smoking-related cancers). Findings from the study indicate that depression and anxiety are not related to increased risk for most cancer outcomes, except for lung and smoking-related cancers. This study shows that key covariates are likely to explain the relationship between depression, anxiety, and lung and smoking-related cancers. Link to publication: https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34853 Link to Neuroscience News article: https://neurosciencenews.com/depression-anxiety-cancer-23769/    

COVID Global Mental Health Consortium Funded – 23 cohorts with 2.8 million participants

We’re excited to share that the collaborative project, “International Evaluation of Modifiable Social Determinants of Health on COVID-related Mental Health Outcomes” has been approved for funding from the National Institute of Mental Health (Mental Health Research Grant, award number 1RF1MH134638-01). Led by Dr. Jordan Smoller (Harvard University, Massachusetts General Hospital), Dr. Sarah Bauermeister (University of Oxford), and Dr. André Russowsky Brunoni (University of Sao Paulo), the COVID Global Mental Health Consortium (CGMHC) will produce a global evaluation of pandemic-related mental health outcomes using individual-level harmonized longitudinal data. The CGHMC is comprised of 23 global cohorts representing 2.8 million participants.1  This work will address critical knowledge gaps related to the impact of policy, psychological and social factors on mental health in the COVID-19 pandemic. 2 We look forward to participating in the CGHMC and contributing to this important research.   1 CGMHC cohorts include CanPath, Health and Retirement Study, Brains for Dementia Research, English Longitudinal Study of Ageing, National Study of Health and Development, Oxwell, Generation Scotland, UK Biobank, Igana Mayuge Health and Demographic Surveillance Site, Adolescent Brain Cognitive Development Study, All of Us, Einstein Study, Mass Gen Brigham Biobank, Study to Assess Risk and Resilience in Service Members Longitudinal Study, COVID-19 Mental Health Survey, FinnGen, Taiwan Biobank, University of College London COVID Study, The Irish Longitudinal Study on Ageing, COVIDMENT, Qatar Biobank, Brazilian High Risk Cohort Study, and the Brazilian Longitudinal Study of Adult Health (ELSA). 2 CanPath was represented on this application by Dr. Ellen Sweeney, Dr. Philip Awadalla, Dr. Robin Urquhart, and Mr. Yunsong Cui. Atlantic PATH is pleased to lead this work on behalf of CanPath.

Pan-Canadian Cancer Data Strategy

The Canadian Cancer Society (CCS) and Canadian Partnership Against Cancer (CPAC) have launched the Pan-Canadian Cancer Data Strategy that will guide efforts to enhance the collection, integration and use of cancer data. “CPAC and CCS have worked with various partners, including provincial and territorial cancer agencies and programs, healthcare organizations, First Nations, Inuit and Métis partners, researchers, policymakers and people with lived cancer experience to create a cancer-specific data strategy that includes: a framework to guide the mission, vision, values and success factors for improvements in cancer data three priorities for action and investment including: improving the efficiency, timeliness and quality of data capture and access enhancing linkages to current data filling gaps in current data collection and availability a section on the importance of First Nations, Inuit and Métis data sovereignty, with examples of First Nations, Inuit and Métis-led efforts to improve data and data governance.” CanPath, and its seven regional cohorts including Atlantic PATH, are proud to be represented in the new Pan-Canadian Cancer Data Strategy.  We’re committed to filling gaps in data on risk factors to guide cancer prevention efforts.  CPAC Press Release: https://www.partnershipagainstcancer.ca/about-us/corporate-resources-publications/pan-canadian-cancer-data-strategy/

CSEB Conference Update

The CanPath team was well represented at the Canadian Society for Epidemiology & Biostatistics (CSEB) Conference in Halifax on June 26-28, 2023. We had representatives from the CanPath National Coordinating Centre, Atlantic PATH, CARTaGENE, the Manitoba Tomorrow Project, and the Ontario Health Study that showcased the groundbreaking research and resources available related to epidemiology and biostatistics within CanPath and the regional cohorts. Throughout the conference, CanPath and the regional cohorts were well-represented in various sessions and discussions, particularly regarding data linkage. Some notable presentations included: ? Dr. Robin Urquhart, Scientific Director of Atlantic PATH, co-presented a workshop on data repositories in Canada ? Dr. Ellen Sweeney, Research Director of Atlantic PATH, presented at a concurrent session about research at Atlantic PATH exploring environmental exposure to arsenic and cancer risk using toxicological and machine-learning methods ? Dr. Vikki Ho, co-Scientific Director of CARTaGENE, co-presented a workshop on mentorship for junior faculty and funding opportunities ? Nicholas Cheng, PhD candidate at the Ontario Institute for Cancer Research, presented at a concurrent session about his research on leveraging population health cohorts to identify cancer biomarkers in blood up to seven years before diagnosis ? Poster sessions featured CanPath, the Manitoba Tomorrow Project, the Ontario Health Study, CARTaGENE, and more, showcasing the exceptional research happening at the regional level and how they can support epidemiological and biostatistical projects. Please connect with us to learn more about these projects. We are proud to contribute to advancing this critical field and look forward to continuing our efforts to drive positive health outcomes for all.                                   #CSEBConference2023 #Epidemiology #Biostatistics #EveryoneCounts #HealthResearch #Cohort #PopulationHealth

CanPath Representation at the Canadian Society for Epidemiology and Biostatistics Conference

We’re so glad to have representation from Atlantic PATH, CARTaGENE, Manitoba Tomorrow Project, Ontario Health Study, and CanPath at the Canadian Society for Epidemiology and Biostatistics Conference in Halifax this week! CanPath and the regional cohorts are well represented in the following sessions: Monday, June 26, 2023 Workshop 1 – Mentorship for Junior Faculty and Funding Opportunities: How to Break into the Game as a Junior Faculty Member [Dr. Vikki Ho, Scientific Co-Director, CARTaGENE] Workshop 3 – Data Repositories in Canada: Overview and Data Access 101  [Dr. Robin Urquhart, Scientific Director, Atlantic PATH] Tuesday, June 27, 2023 Concurrent Sessions B5: Lifecourse and Chronic Disease Epidemiology – Leveraging population health cohorts to identify cancer biomarkers in blood up to seven years prior to diagnosis          Presenter: Nicholas Chang, PhD candidate, OICR Poster Session   The Impact of Alcohol Consumption and Single Nucleode Polymorphisms on the High Rates of Colorectal Cancer in Atlantic Canada                                                                   Presenter: Carlee Feinstein, Research Assistant, St. FX                                                                                                                                                                                                        Authors: Carlee A Feinstein, Derrick G Lee, Allison Walsh, Tiffany S Bondo           The Manitoba Tomorrow Project: A Canadian Cohort Presented by: Dr. Travis Hrubeniuk, Project Lead, Manitoba Tomorrow Project Authors: Travis Hrubeniuk, Sachin Katyal, Donna Turner Canadian Partnership for Tomorrow’s Health (CanPath): Celebrang Compleng the Provincial Map and Cross-Province Data Linkage Presented by: Dr. John McLaughlin, Executive Director, CanPath Authors: John McLaughlin, Riaz Alvi, Philip Awadalla, Parveen Bhatti, Trevor Dummer, Jason Hicks, Vikki Ho, Grace Shen-Tu, Kimberly Skead, Ellen Sweeney, Donna Turner, Robin Urquhart, Jennifer Vena Examining the impact of inflammatory bowel disease on colorectal cancer risk in Atlantic Canada Presented by: Livia Clarke, Research Assistant, Dalhousie Medical School / St. FX Authors: Livia Clarke, Derrick Lee, Ellen Sweeney The Impact of Abnormal Sleep and Circadian Disruption on Atlantic Canada’s High Rate of Colorectal Cancer Presented by: Alison Walsh, Research Assistant, St. FX Authors: Alison J Walsh, Carlee A Feinstein, Tiffany S Bondoc, Megan K MacGillivray, Derrick G Lee The Ontario Health Study (OHS) Presented by: Sarah Salih, Data Analyst, Ontario Health Study Authors: Victoria Kirsh, Kimberly Skead, Kelly McDonald, Nancy Kreiger, Julian Lile, Karen Menard, John McLaughlin, Sutapa Mukherjee, Lyle Palmer, Vivek Goel, Mark Purdue, Sarah Salih, Philip Awadalla Smoking, aberrant DNA methylaon of the F2RL3 and AHRR genes, and lung cancer risk                                                                                                                                                     Presented by: Vikki Ho, Scientific Co-Director, CARTaGENE                                                                                                                                                                                                         Authors: Alice Nguyen, Anita Koushiki, Laura Pelland-St. Pierre, Michael Pham, Romain Pasquet, Sherryl Tauylor, Delphine Bosson-Rieutort, Vikki Ho The influence of occupaonal risk factors on DNA methylaon in the AHRR and F2RL3 genes Presented by: Laura Pelland-St-Pierre Authors: Michael Pham, Laura Pelland-St-Pierre, Alice Nguyen, Romain Pasquet, Sherryl Taylor, Delphine Bosson-Rieutort, Anita Koushik, Vikki Ho Wednesday, June 28, 2023 Concurrent Session C5: Cancer Epidemiology II – Exploring Environmental Exposure to Arsenic and Cancer Risk in the Atlantic PATH Cohort using Toxicological and Machine Learning Methods Presenter: Dr. Ellen Sweeney, Research Director, Atlantic PATH Please feel free to contact Atlantic PATH, CanPath or any of the regional cohorts to learn more about these projects!

CanPath Access Office Hours

The CanPath Access Office invites researchers to an Office Hours session. This virtual series provides researchers with an opportunity to ask questions about CanPath data and biosamples and the access process. Members of the Access Office will be available to answer questions and demonstrate how to navigate the CanPath Portal and online application. Registration: https://us02web.zoom.us/meeting/register/tZYsc-ugqD8sH9QfdxDq2NPHtBttkD17yCz1#/registration  

Most CanPath study participants had infection-acquired antibodies but few suspected COVID-19

Dr. Victoria Kirsh presented at a CanPath webinar this week to present results from the SUPPORT-Canada study, funded by the federal COVID-19 Immunity Task Force (CITF). Data and blood spot samples were used from 22,300 participants from Atlantic PATH, CARTaGENE, the Ontario Health Study, Manitoba Tomorrow Project, Alberta’s Tomorrow Project, and BC Generations. Key findings include: 62% of participants had a COVID-19 infection based on anti-N measured antibody levels. Among those, 86% did not suspect they had ever had COVID-19. 95% of the COVID-19 infections were observed during the Omicron period. Risk of infection was increased among younger individuals, males, essential workers, and those who travelled. Participants with a reported COVID-19 infection reported symptoms from mild to severe, but few required hospitalization. The effectiveness of full or booster vaccination in preventing COVID-19 Omicron infection is short-term, only lasting 4 months. Time since last dose is a more important determinant of protection against infection than the number of doses. Antibody levels are correlates of vaccine-induced protection. Prior COVID-19 infection protects against reinfection for 8 months. The CanPath SUPPORT-Canada study has provided important findings related to the COVID-19 pandemic, vaccines and infections. With only 4 months of protection, these findings suggest that booster campaigns could be strategically used to rapidly boost immunity before upcoming waves of infection. Further, the longitudinal nature of CanPath participants ensures that we have a nationally representative population that can be followed for years to come (e.g., impact of Long COVID, future vaccinations, etc.). Link to recorded webinar: To come Link to webinar slide deck: https://www.covid19immunitytaskforce.ca/wp-content/uploads/2023/05/canpath-webinar-may-2023.pdf Link to CITF’s post: https://www.covid19immunitytaskforce.ca/most-canpath-study-participants-had-infection-acquired-antibodies-but-few-suspected-covid-19/